Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PTGFR | P43088 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622585 | 0.83 | ALK (0.46) | RXFP1KMT2AGAAMAPTPOLB | |
| SCHEMBL1621274 | 0.82 | THRB (0.52) | RXFP1MAPK1SMN1; SMN2HTTTDP1 | |
| SCHEMBL4714364 | 0.82 | MAPT (0.57) | KMT2AMAPTPOLBMAPK1HIF1A | |
| SCHEMBL3497699 | 0.80 | HTT (0.49) | RXFP1KMT2ANT5EMAPK1HTT | |
| SCHEMBL1083824 | 0.80 | CYP1A2 (0.50) | RXFP1KMT2AMAPTPOLBMAPK1 | |
| SCHEMBL1084151 | 0.77 | HIF1A (0.71) | KMT2AMAPTMAPK1HIF1APTGFR | |
| SCHEMBL1083817 | 0.76 | HIF1A (0.73) | KMT2AMAPTMAPK1HIF1AMEN1 | |
| SCHEMBL1083892 | 0.74 | HIF1A (0.57) | KMT2AMAPTPOLBMAPK1HIF1A | |
| SCHEMBL4715753 | 0.72 | TGFBR1 (0.44) | MAPTHIF1APTGFR | |
| SCHEMBL3459657 | 0.72 | HTT (0.49) | RXFP1KMT2AMAPTNT5EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1603908-B1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1603908-B1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1603908-A1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040204431-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004081009-A1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204431-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFBR2, TGFB2 | RXFP1 824/4885KMT2A 2127/4885GAA 533/4885 |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | TGFB1, TGFB2, TGFBR1 | RXFP1 1487/4885KMT2A 2427/4885GAA 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.